Not provided
Not provided
Not provided
Not provided
Failure to recruit due to human resourcing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Glasgow | OTHER |
Not provided
Not provided
Not provided
Not provided
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of kidney failure, with high levels of glycohaemoglobin (HbA1c) presenting a sharper decline in renal function and an increase in the risk of mortality and end-stage renal disease (ESRD). Polyphenols may improve renal insufficiency in patients with diabetes with chlorogenic acids (CGA) one of the principle polyphenol groups in the diet - coffee/tea, stone fruits (especially plums/prunes) and some vegetables (artichoke, chicory). CGA (3-4 cups of coffee) has been associated with 25% lower risk of T2DM and a favourable reduction of HbA1c, blood pressure, and oxidative stress levels. This randomised controlled trial, therefore, aims to evaluate the effect of high CGA food on glycation and oxidative stress in T2DM subjects with early renal insufficiency (glomerular filtration rate of 35-60 mL/min) as well as progression of renal insufficiency and the risk of cardiovascular diseases.
The study will have two phases - phase I, an interventional study of 3 months followed by phase II, an observational study of 21 months.
In phase I, subjects will be randomized into 2 groups: CGA-enriched diet group, or control (habitual) diet group. The treatment group will be provided with a chlorogenic acid-rich food (coffee) with instructions to achieve an intake of 400 mg per day (equivalent to 3-4 coffee cups per day) for 12 weeks. The control group will receive a conventional coffee low in chlorogenic acid.
Participants will attend three sessions during phase I; baseline, 6 weeks, and 12 weeks. At baseline, general information, medical history, dietary habits and medication use will be recorded and a Food Frequency Questionnaire completed. Urine and blood samples will be collected and blood pressure, waist circumference, height and weight recorded. Participants' diet over the previous 3 days will be assessed by estimated food diary analysis.
In phase II, written dietary recommendations will be provided at three time points (months 6, 12 and 24) - treatment group to achieve a CGA-rich diet (total polyphenol intake of at least 1g per day, and at least 400mg per day of CGA) and standard dietary advice for the control group. Anthropometric/dietary data will be collected as well as blood and urine samples to assess markers of renal function, glycation and oxidative stress, and proteomic markers of cardiovascular disease, coronary artery disease and diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment group | Experimental | Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee) |
|
| Control group | Sham Comparator | Conventional coffee (habitual diet) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chlorogenic Acid (CGA) enriched coffee | Dietary Supplement | Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg. Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in glycohaemoglobin (HbA1c) | 3 months | |
| Change in estimated glomerular filtration rate (eGFR) | 21 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in fasting glucose | 3 months | |
| Change in fructosamine | 3 months | |
| Change in advanced glycation end product (AGE) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emilie Combet, PhD | University of Glasgow | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NHS Greater Glasgow and Clyde | Glasgow | United Kingdom | ||||
| University of Glasgow |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002726 | Chlorogenic Acid |
| ID | Term |
|---|---|
| D002934 | Cinnamates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Conventional coffee | Dietary Supplement | Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice |
|
|
| 3 months |
| Change in soluble receptor for AGE (sRAGE) | 3 months |
| Change in F2-isoprostane | 3 months |
| Change in malondialdehyde (MDA) | 3 months |
| Change in Urinary Albumin Excretion | 21 months |
| Change in creatinine | 21 months |
| Change in blood pressure | 21 months |
| Change in crystatin C | 21 months |
| Change in fibrinogen | 21 months |
| Change in cholesterol | 21 months |
| Change in C-reactive protein | 21 months |
| Change in Interleukin-6 | 21 months |
| Change in thiobarbituric acid reactive substances (TBARS) | 21 months |
| Change in advanced oxidation protein products (AOPP) | 21 months |
| Change in 8hydroxy 2'deoxyguanoside (8OhdG) | 21 months |
| Glasgow |
| United Kingdom |
| D004700 | Endocrine System Diseases |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003509 |
| Cyclohexanecarboxylic Acids |